Diagnostics of contrastinduated nephropathy after percutaneous coronary intervention

A. V. Pyrochkin; A. M. Prystrom; V. S. Pilotovich; D. N. Horetskaya; T. M. Yuraga; T. D. Borisenko; E. A. Varabyova; O, M. Solovey; P. F. Chernoglaz; V. V. Veselov; I. E. Lushnikova; S. E. Piskunov

doi:10.29235/1814-6023-2019-16-2-175-184

Diagnostics of contrastinduated nephropathy after percutaneous coronary intervention

A. V. Pyrochkin, A. M. Prystrom, V. S. Pilotovich, D. N. Horetskaya, T. M. Yuraga, T. D. Borisenko, E. A. Varabyova, O, M. Solovey, P. F. Chernoglaz, V. V. Veselov, I. E. Lushnikova, S. E. Piskunov

https://doi.org/10.29235/1814-6023-2019-16-2-175-184

Full Text:

PDF (Rus) |

Generate QR code

Abstract

The present study is devoted to search for the opportunities of early diagnosis of the development of contrastinduced nephropathy when performing coronary angiography and percutaneous coronary intervention in patients with a chronic ischemic heart disease. The predicative ability of modern biomarkers was studied in comparison with serum creatinine. Baseline serum β2-microglobulin levels >1.1 mg/l can be attributed to patients at a high risk of developing complications. Increasing the level of cystatin C in the blood by 25 % from baseline after 24 hours or >1.064 mg/l, increasing the level of β2-microglobulin in blood after 24 hours > 1.42 mg/l allows you to diagnose acute kidney damage, before the creatinine dynamics and can be used in routine clinical practice. The determination of neutrophil lipocalin in the urine improves the accuracy of diagnosis, but is difficult in routine practice.

Keywords

contrast-induced nephropathy, coronary heart disease, cystatin C, β2-microglobulin, neutrophil lipocalin

References

1. Fliser D., Laville M., Covic A., Fouque D., Vanholder R., Juillard L., Van Biesen W. European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: defnitions, conservative management and contrast-induced nephropathy. Nephrology Dialysis Transplantation, 2012, vol. 27, no. 12, pp. 4263-4272. https://doi.org/10.1093/ndt/gfs375

2. Haase-Fielitz A., Haase M., Bellomo R. Instability of NGAL during long-term storage. American Journal of Kidney Diseases, 2009, vol. 53, no. 3, pp. 564-565. https://doi.org/10.1053/j.ajkd.2009.01.009

3. Mishra J., Dent C., Tarabishi R., Mitsnefes M. M., Ma Q., Kelly C. [et al.]. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker of acute renal injury after cardiac surgery. Lancet, 2005, vol. 365, no. 9466, pp.1231-1238. https://doi.org/10.1016/S0140-6736(05)74811-X

4. Abosaif N. Y., Tolba Y. A., Heap M., Russell J., El Nahas A. M. The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability. American Journal of Kidney Diseases, 2005, vol. 46, no. 6, pp. 1038-1048. https://doi.org/10.1053/j.ajkd.2005.08.033

5. GFR Calculator. National Kidney Foundation. Available at: http://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm (accessed 01.12.2018).

6. Mehran R., Aymong E. D., Nikolsky E., Lasic Z., Iakovou I., Fahy M. [et al.]. A simple risk score for prediction contrast-indused nephropathy after percutaneous coronary intervention: development and initial validation. Journal of the American College of Cardiology, 2004, vol. 44, no. 7, pp. 1393-1399. https://doi.org/10.1016/j.jacc.2004.06.068

7. Neumann F.-J., Sousa-Uva M., Ahlsson A., Alfonso F., Banning A. P., Benedetto U. [et al.]. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, vol. 40, no. 2, pp. 87-165. https://doi.org/10.1093/eurheartj/ehy394

8. Stacul F., Van der Molen A. J., Reimer P., Webb J. A., Thomsen H. S., Morcos S. K. [et al.]. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. European Radiology, 2011, vol. 21, no. 12, pp. 2527-2541. https://doi.org/10.1007/s00330-011-2225-0

9. Wang M., Zhang L., Yue R., You G., Zeng R. Signifcance of cystatin C for early diagnosis of contrast-induced nephropathy in patients undergoing coronary angiography. Medical Science Monitor, 2016, vol. 22, pp. 2956-2961. https://doi.org/10.12659/msm.897241

10. Cecchi E., Avveduto G., D’Alfonso M. G., Terreni A., Gelera E., Caldini A., Giglioli C. Cystatin C, but not urinary or serum NGAL, may be associated with contrast induced nephropathy after percutaneous coronary invasive procedures: a single center experience on a limited number of patients. Acta Medica Academica, 2017, vol. 46, no. 1, pp. 34-43. https://doi.org/10.5644/ama2006-124.184

11. Shukla A. N., Juneja M., Patel H., Shah K. H., Konat A., Thakkar B. M., Madan T., Prajapati J. Diagnostic accuracy of serum cystatin C for early recognition of contrast induced nephropathy in Western Indians undergoing catheterization. Indian Heart Journal, 2017, vol. 69, no. 3, pp. 311-315. https://doi.org/10.1016/j.ihj.2016.12.010

12. Singer E., Elger A., Elitok S., Kettritz R., Nickolas T. L., Barasch J., Luft F. C., Schmidt-Ott K. M. Urinary neutrophil gelatinase-associated lipocalin distinguishes prerenal from in trans renal failure and predict outcomes. Kidney International, 2011, vol. 80, no. 4, pp. 405-414. https://doi.org/10.1038/ki.2011.41

13. Nozue T., Michishita I., Mizuguchi I. Predictive value of serum cystatin C, β2-microglobulin, and urinary liver-type fatty acid-binding protein on the development of contrast-induced nephropathy. Cardiovascular Intervention and Therapeutics, 2010, vol. 25, no. 2, pp. 85-90. https://doi.org/10.1007/s12928-010-0014-3

14. Kafkas N., Liakos C., Zoubouloglou F., Dagadaki O., Dragasis S., Makris K. Neutrophil gelatinase-associated lipocalin as an early marker of contrast-induced nephropathy after elective invasive cardiac procedures. Clinical Cardiology, 2016, vol. 39, no. 8, pp. 464-470. https://doi.org/10.1002/clc.22551

15. Ashalatha V. L., Bitla A. R., Kumar V. S., Rajasekhar D., Suchitra M. M., Lakshmi A. Y., Rao P. V. Biomarker response to contrast administration in diabetic and nondiabetic patients following coronary angiography. Indian Journal of Nephrology, 2017, vol. 27, no. 1, pp. 20-27. https://doi.org/10.4103/0971-4065.179335

For citations:

Pyrochkin A.V., Prystrom A.M., Pilotovich V.S., Horetskaya D.N., Yuraga T.M., Borisenko T.D., Varabyova E.A., Solovey O.M., Chernoglaz P.F., Veselov V.V., Lushnikova I.E., Piskunov S.E. Diagnostics of contrastinduated nephropathy after percutaneous coronary intervention. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2019;16(2):175-184. (In Russ.) https://doi.org/10.29235/1814-6023-2019-16-2-175-184

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1814-6023 (Print)
ISSN 2524-2350 (Online)

Proceedings of the National Academy of Sciences of Belarus, Medical series

Diagnostics of contrastinduated nephropathy after percutaneous coronary intervention

Full Text:

Abstract

Keywords

About the Authors

References

Review

For citations:

Username
Password
	Remember me

User

Proceedings of the National Academy of Sciences of Belarus, Medical series

Diagnostics of contrastinduated nephropathy after percutaneous coronary intervention

Full Text:

Abstract

Keywords

About the Authors

References

Review

For citations:

Cookies policy